MedPath
HSA Approval

PAZOPANIB-TEVA FC TABLETS 200 MG

SIN17000P

PAZOPANIB-TEVA FC TABLETS 200 MG

PAZOPANIB-TEVA FC TABLETS 200 MG

May 8, 2024

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

L01XE11

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

PharOS MT Ltd

Active Ingredients

Pazopanib hydrochloride eqv Pazopanib

200 mg

Pazopanib

Documents

Package Inserts

Pazopanib Teva PI.pdf

Approved: May 8, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PAZOPANIB-TEVA FC TABLETS 200 MG - HSA Approval | MedPath